Literature DB >> 8239613

Fluconazole resistance in Candida glabrata.

C A Hitchcock1, G W Pye, P F Troke, E M Johnson, D W Warnock.   

Abstract

We report a case of infection with Candida glabrata in which the organism became resistant to fluconazole and in which pre- and posttreatment isolates were available for comparison. The organism was cross-resistant to ketoconazole and itraconazole, in common with other azole-resistant yeasts. Fluconazole was a potent inhibitor of cytochrome P-450-dependent 14 alpha-sterol demethylase (P-450DM) in lysates of cells from both susceptible and resistant cultures (50% inhibitory concentration, 0.2 microM), indicating that resistance was unrelated to changes in P-450DM. Instead, it appeared to arise from a permeability barrier to fluconazole, since resistant cells were unable to take up radiolabelled drug.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8239613      PMCID： PMC188100          DOI： 10.1128/AAC.37.9.1962

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  The effect of different fatty acid and sterol composition on the erythritol flux through the cell membrane of Acholeplasma laidlawii.

Authors:  B de Kruyff; W J de Greef; R V van Eyk; R A Demel; L L van Deenen
Journal:  Biochim Biophys Acta       Date:  1973-03-16

2.  Fluconazole resistance in Candida glabrata.

Authors:  D W Warnock; J Burke; N J Cope; E M Johnson; N A von Fraunhofer; E W Williams
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

Review 3.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

4.  Miconazole-resistant Candida.

Authors:  R J Holt; A Azmi
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

Review 5.  Sterols in Candida albicans mutants resistant to polyene or azole antifungals, and of a double mutant C. albicans 6.4.

Authors:  C A Hitchcock; N J Russell; K J Barrett-Bee
Journal:  Crit Rev Microbiol       Date:  1987       Impact factor: 7.624

6.  Inhibition of 14 alpha-sterol demethylase activity in Candida albicans Darlington does not correlate with resistance to azole.

Authors:  C A Hitchcock; K J Barrett-Bee; N J Russell
Journal:  J Med Vet Mycol       Date:  1987-10

7.  Cytochrome P-450-dependent 14 alpha-demethylation of lanosterol in Candida albicans.

Authors:  C A Hitchcock; S B Brown; E G Evans; D J Adams
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

8.  The mode of antifungal action of tolnaftate.

Authors:  K J Barrett-Bee; A C Lane; R W Turner
Journal:  J Med Vet Mycol       Date:  1986-04

9.  The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans.

Authors:  C A Hitchcock; K J Barrett-Bee; N J Russell
Journal:  J Gen Microbiol       Date:  1986-09

10.  The lipid composition and permeability to the triazole antifungal antibiotic ICI 153066 of serum-grown mycelial cultures of Candida albicans.

Authors:  C A Hitchcock; K J Barrett-Bee; N J Russell
Journal:  J Gen Microbiol       Date:  1989-07
View more
  64 in total

1.  Systemic antifungal drugs: Are we making any progress?

Authors:  M Laverdière
Journal:  Can J Infect Dis       Date:  1994-03

2.  Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Authors:  J Brieland; D Essig; C Jackson; D Frank; D Loebenberg; F Menzel; B Arnold; B DiDomenico; R Hare
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Phenotypic switching in Candida glabrata involves phase-specific regulation of the metallothionein gene MT-II and the newly discovered hemolysin gene HLP.

Authors:  S A Lachke; T Srikantha; L K Tsai; K Daniels; D R Soll
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.

Authors:  Annemarie Borst; Maria T Raimer; David W Warnock; Christine J Morrison; Beth A Arthington-Skaggs
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 5.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

6.  In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp.

Authors:  H M Wardle; D Law; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

7.  Deletion of the DNA Ligase IV Gene in Candida glabrata Significantly Increases Gene-Targeting Efficiency.

Authors:  Yuke Cen; Alessandro Fiori; Patrick Van Dijck
Journal:  Eukaryot Cell       Date:  2015-06-05

8.  Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).

Authors:  Amar Safdar; Vishnu Chaturvedi; Brian S Koll; Davise H Larone; David S Perlin; Donald Armstrong
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 9.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

10.  In vitro activity of a new polyene, SPA-S-843, against yeasts.

Authors:  C Rimaroli; T Bruzzese
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.